Funding for this research was provided by:
Alzheimer's Drug Discovery Foundation
Novo Nordisk UK Research Foundation
Van Geest Foundation
Received: 23 March 2018
Accepted: 27 February 2019
First Online: 3 April 2019
Change Date: 19 July 2020
Change Type: Correction
Change Details: An amendment to this paper has been published and can be accessed via the original article.
Ethics approval and consent to participate
: This study was approved by the local and regional regulatory ethics committees (London Riverside Research Ethics Committee – study reference number 13/LO/0699, and Health Research Authority, UK), and the Medicines and Healthcare products Regulatory Agency (MHRA – EudraCT number 2013–000962-13). Approval for administration of radioactivity was given by the Administration of Radioactive Substances Advisory Committee (ARSAC).All participants and study partners signed an Informed Consent Form prior to entry into the study.
: Dr Edison was funded by the Medical Research Council and now by the Higher Education Funding Council for England (HEFCE). He has also received grants from Alzheimer’s Research, UK, Alzheimer’s Drug Discovery Foundation, Alzheimer’s Society, UK, Novo Nordisk, GE Healthcare, Astra Zeneca, Pfizer, Eli Lilly and Piramal Life Sciences. The other authors have nothing to declare.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.